Sorcero has announced the closing of a $42.5 million Series B funding round, brings the company’s total funding to $59 million.
The investment was led by US-based NewSpring Growth, with participation from other US-based venture capital firms Leawood Venture Capital and Blu Ventures.
The AI platform provider plans to use the new capital to accelerate global expansion across medical affairs, safety, scientific communications, and medical device markets. The funding will also support ongoing development of Sorcero’s platform, which is designed to help life sciences companies generate insights and improve the adoption of complex therapies.
AI Platform Already in Use Across Pharma
Sorcero reports that one-third of the top 30 global pharmaceutical companies are already using its platform to analyze medical data and produce scientific evidence. The company says customers are seeing productivity improvements of up to 92%, faster insight generation by 72%, and accelerated delivery of manuscripts and clinical evidence—shortening timelines by up to five months.
The Sorcero Intelligence Platform includes several AI-driven modules focused on medical insights, publications, safety workflows, and medical device applications. The technology is purpose-built for regulated healthcare environments, with privacy and compliance frameworks that support global data governance requirements.
CEO and co-founder Dipanwita Das stated that the platform is designed to enable a “unified intelligence model” that aligns with the shift toward precision medicine. “We’re pioneering a new evidence-based medical affairs model where science, personalized for physicians, drives engagement and product adoption,” Das said.
Market Conditions Driving Demand
The company points to industry challenges that it aims to address, including the rapid rise of precision medicine and specialty drugs, which now represent more than 80% of new approved therapies, as per the company. Despite significant R&D investment, many treatments struggle to gain rapid coverage or adoption, with 76% of new products achieving less than 50% payor coverage within six months.
Additionally, Sorcero cites research indicating that 70% of healthcare professionals believe pharmaceutical representatives lack understanding of their clinical needs, while 62% report being overwhelmed by irrelevant content. These gaps contribute to slower uptake of new therapies and inconsistent evidence delivery.
Sorcero’s platform integrates hundreds of medical data sources, including publications, congress proceedings, real-world evidence, and safety records. Its AI models are trained to clinical accuracy standards, achieving 96.1% inclusion accuracy, exceeding FDA benchmarks, and aligning with medical domain expertise, according to the company.
Other investors pointed to the platform’s scalability and defensible data advantage. “There’s a lot of hype around AI, but few companies deliver measurable value at scale,” said Dan Goldsmith, a life sciences software investor. He added that Sorcero’s technology could help life sciences organizations improve therapy adoption in an increasingly evidence-driven commercial landscape.
The funding follows Sorcero’s partnerships with Google Cloud, Springer Nature, Snowflake, and others, as well as its recent acquisition of Axiom Health to support expansion into medical device markets. The platform is now available through the NIH STRIDES program, Google Cloud Marketplace, and commercial marketplaces.
